Table 3.

Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (for Pheno age acceleration).

	10-year overall survival			10-year recurrence-free survival
	Univariate model	Multivariablea model		Univariate model	Multivariableb model
	HR (95% CI)	HR (95% CI)	FDR	HR (95% CI)	HR (95% CI)	FDR
NLR	1.49 (1.37–1.62)	1.36 (1.23–1.50)	6.9 × 10−9	1.14 (1.06–1.22)	1.10 (1.01–1.18)	0.046
Memory B cell	0.82 (0.72–0.94)	0.89 (0.78–1.02)	0.13	0.94 (0.87–1.03)
Naïve B cell	0.86 (0.79–0.94)	0.93 (0.86–1.00)	0.09	0.99 (0.94–1.04)
Memory CD4T cell	0.92 (0.90–0.95)	0.95 (0.93–0.98)	3.8 × 10−3	0.97 (0.96–0.99)	0.98 (0.96–0.99)	0.046
Naïve CD4T cell	0.87 (0.82–0.93)	0.98 (0.92–1.04)	0.48	0.95 (0.92–0.99)	0.99 (0.95–1.02)	0.46
Memory CD8T cell	0.96 (0.94–0.99)	0.95 (0.93–0.98)	3.8 × 10−3	0.99 (0.97–1.01)
Naïve CD8T cell	0.84 (0.73–0.96)	1.21 (1.04–1.41)	0.03	0.93 (0.86–1.02)
Monocyte	1.06 (1.02–1.11)	1.01 (0.96–1.06)	0.74	1.05 (1.02–1.08)	1.03 (1.00–1.07)	0.07
Neutrophil	1.06 (1.05–1.08)	1.04 (1.03–1.06)	2.0 × 10−6	1.01 (1.00–1.02)	1.01 (0.99–1.02)	0.31
Regulatory T cell	1.27 (1.08–1.49)	1.16 (0.98–1.36)	0.12	1.20 (1.06–1.35)	1.17 (1.03–1.32)	0.046
NK cell	0.92 (0.87–0.98)	0.92 (0.86–0.98)	0.03	0.98 (0.94–1.02)
Basophil	1.51 (1.24–1.85)	1.26 (1.01–1.56)	0.07	1.16 (0.99–1.35)
Eosinophil	1.02 (0.95–1.10)			1.03 (0.98–1.08)

Note: Winsorization was used on the top 2% or the last 2% (only Neu) values for fitting linearity assumption.

Abbreviations: CI, confidence interval; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; NMIBC, non-muscle-invasive bladder cancer.

^aThe model controlling for age, sex, tumor grade, smoking status, BCG treatment status, and Pheno age acceleration.

^bThe model controlling for age, stratified sex, tumor grade, smoking status, stratified BCG treatment status, and Pheno age acceleration.